Pembrolizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Trial Timeline
Oct 1, 2016 → Apr 9, 2024
NCT ID
NCT02955758About Pembrolizumab
Pembrolizumab is a phase 2 stage product being developed by Merck for Metastatic Non-Squamous Non-Small Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02955758. Target conditions include Metastatic Non-Squamous Non-Small Cell Lung Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non-Squamous Non-Small Cell Lung Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02083484 | Pre-clinical | Completed |
| NCT07302347 | Phase 1/2 | Recruiting |
| NCT07089992 | Phase 2 | Recruiting |
| NCT07007273 | Phase 2 | Recruiting |
| NCT04569461 | Phase 2 | Withdrawn |
| NCT05815927 | Phase 3 | Recruiting |
| NCT05852223 | Phase 2 | Recruiting |
| NCT05879120 | Phase 2 | Withdrawn |
| NCT06004336 | Phase 2 | Recruiting |
| NCT05496036 | Phase 2 | Recruiting |
| NCT05131919 | Phase 2 | Active |
| NCT05197322 | Phase 2 | Recruiting |
| NCT05406713 | Phase 2 | Active |
| NCT05025813 | Phase 2 | Recruiting |
| NCT06413095 | Phase 1 | Completed |
| NCT05191472 | Phase 2 | Terminated |
| NCT05204160 | Phase 2 | Withdrawn |
| NCT04575961 | Phase 2 | Active |
| NCT04417166 | Phase 2 | Recruiting |
| NCT05188508 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Non-Squamous Non-Small Cell Lung Carcinoma